Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers.
Target Price
The average target price of ECOR is 20 and suggests 229% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell